(917) 310-3371
Egrifta WR is tesamorelin for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It targets a specific clinical problem and is not a general weight-loss medicine.
Check the box and vial say Egrifta WR before using the instructions taught at your visit. WR and SV are not interchangeable. WR is reconstituted weekly to provide daily injections; it is not a weekly dose. Have the clinician or pharmacist demonstrate mixing, dose measurement, storage, site rotation and disposal for this formulation, and confirm what to do if a dose or vial is missed or compromised. Do not substitute an online research peptide or another product's diluent. Bring pregnancy, cancer/pituitary history and baseline metabolic information, and book IGF-1/glucose monitoring and response review.
Egrifta WR is tesamorelin for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It targets a specific clinical problem and is not a general weight-loss medicine. An evaluation distinguishes visceral abdominal fat from ordinary weight gain, fluid retention and other causes of an enlarged abdomen. The benefit being assessed is a change in the indicated fat accumulation, not a promise of weight loss or prevention of heart disease.
Tesamorelin is an analogue of growth hormone-releasing factor. It stimulates growth hormone release and increases IGF-1, which is part of its effect and safety monitoring. It is not antiretroviral treatment and does not suppress HIV. Continue the HIV regimen prescribed by your HIV clinician unless that clinician changes it.
The indication is for adults with excess abdominal fat associated with HIV lipodystrophy. Egrifta WR is contraindicated in pregnancy, active malignancy, hypersensitivity and conditions that disrupt the hypothalamic-pituitary axis. A past cancer history needs careful review; it is not interchangeable with active cancer. Diabetes, retinopathy, other endocrine conditions and medicines affect evaluation and monitoring. Safety and effectiveness are not established for a general pediatric weight-management program.
Review the pattern of fat change, symptoms, HIV treatment history and prior evaluations. Agree on a measurable goal and how benefit will be judged, rather than treating a scale target as the indication.
The clinician reviews pituitary problems, cancer history, pregnancy, glucose/diabetes status and IGF-1. Diabetic retinopathy may need particular monitoring.
Egrifta WR is injected under the skin daily. ‘WR’ refers to weekly reconstitution of a vial that supplies daily doses; it is not a once-weekly injection. WR and Egrifta SV have different preparation and dosing instructions and are not interchangeable.
Arrange laboratory monitoring, injection follow-up and assessment of clinical benefit. The clinician may stop treatment if risks outweigh benefit or the response is inadequate.
Bring HIV records, your antiretroviral and supplement list, prior abdominal-fat assessments, cancer and pituitary history and recent metabolic results. Tell the clinician about pregnancy plans. Before home use, get hands-on teaching for the exact WR vial, diluent, syringes, daily preparation, storage and disposal. Ask the pharmacist to check the product if packaging differs from the one used in training.
Tesamorelin can raise IGF-1 and blood glucose and cause fluid retention, joint or muscle discomfort and injection-site reactions. Report swelling, significant numbness or symptoms of high blood sugar. Stop and seek urgent care for a severe allergic reaction. A new cancer diagnosis or pregnancy requires immediate contact with the treating clinician. Long-term cardiovascular safety has not been established; improved appearance is not proof that heart-disease risk has fallen.
Follow-up checks IGF-1, glucose and relevant symptoms, along with whether abdominal-fat reduction meets the agreed goal. Monitoring frequency is individualized. Review the daily injection technique and any missed doses, supply problems or side effects. Do not increase doses for a faster response or use research peptides as a substitute. If treatment ends, your clinician discusses what changes may recur and whether another approach is appropriate.
Confirm a clinician with the required HIV/endocrine knowledge, the pharmacy supply route and the exact formulation authorized by the plan. Ask whether documentation of HIV lipodystrophy, baseline tests or prior therapy is required. Medication, supplies, visits and labs can have separate costs.
No. Egrifta WR does not replace antiretroviral HIV treatment. It targets excess abdominal fat in adults with HIV-associated lipodystrophy and is not an ordinary obesity or belly-fat treatment. WR means weekly reconstitution of a vial that supplies daily injections, not one weekly injection. Continue your prescribed HIV regimen and confirm the exact product and treatment plan with the responsible clinician.
Egrifta WR is not interchangeable with Egrifta SV or another tesamorelin formulation. Do not replace its prescribed preparation and dosing with a compounded peptide or assume that sharing an ingredient establishes equivalence, approved use or safety. Ask the HIV clinician and pharmacist to identify the exact product, indication and instructions. Keep HIV treatment separate. Tesamorelin does not replace antiretroviral medicine.
Bring HIV records, your antiretroviral and supplement list, prior abdominal-fat assessments, cancer and pituitary history and recent metabolic results. Tell the clinician about pregnancy plans. Before home use, get hands-on teaching for the exact WR vial, diluent, syringes, daily preparation, storage and disposal. Ask the pharmacist to check the product if packaging differs from the one used in training.
Review the pattern of fat change, symptoms, HIV treatment history and prior evaluations. Agree on a measurable goal and how benefit will be judged, rather than treating a scale target as the indication.
The clinician reviews pituitary problems, cancer history, pregnancy, glucose/diabetes status and IGF-1. Diabetic retinopathy may need particular monitoring.
Egrifta WR is injected under the skin daily. ‘WR’ refers to weekly reconstitution of a vial that supplies daily doses; it is not a once-weekly injection. WR and Egrifta SV have different preparation and dosing instructions and are not interchangeable.
Arrange laboratory monitoring, injection follow-up and assessment of clinical benefit. The clinician may stop treatment if risks outweigh benefit or the response is inadequate.
Ask an HIV clinician to assess excess abdominal fat associated with HIV lipodystrophy and whether tesamorelin is appropriate. Egrifta is not a general weight-loss medicine or a replacement for HIV treatment. Bring cancer/pituitary history, pregnancy information, HIV medicines and metabolic tests. Have the prescriber and pharmacist name the exact formulation, WR or SV, and confirm the prescription, supply and teaching. WR and SV have different dose, mixing and storage instructions and are not substitutable. Approval or an old SV prescription does not prove current pharmacy stock or a Nao treatment pathway.
Tesamorelin reduced visceral abdominal fat in the clinical studies supporting Egrifta. At 26 weeks, the two original-formulation trials showed mean reductions of 18% and 14%. Their respective placebo groups had a 2% increase and a 2% reduction. WR approval also uses evidence of comparable drug exposure to the studied formulation. These are averages for adults with HIV-associated abdominal lipodystrophy, not guaranteed weight loss or proof of cardiovascular benefit. The clinician reviews response together with IGF-1, glucose and adverse effects. Continuing treatment should depend on an adequate benefit and acceptable safety.
Tesamorelin has important risks and contraindications. Egrifta WR must not be used during pregnancy, with active cancer, certain hypothalamic/pituitary disorders or a serious allergy to the product. It can raise IGF-1 and blood glucose and cause fluid retention, joint discomfort and injection reactions. Review cancer history, diabetes/retinopathy and other medicines before treatment and keep the safety tests. Severe allergy needs emergency care. New pregnancy, a cancer diagnosis, marked swelling or symptoms of high blood sugar need prompt contact with the treating clinician. Long-term cardiovascular safety is not established. Do not use an unapproved research peptide as a substitute.
Get practical teaching from the prescribing clinician or pharmacist for the exact box and vial you receive. Egrifta WR and SV are not substitutable. Do not reuse the other formulation’s dose, diluent, mixing or storage directions. WR is mixed weekly to supply daily subcutaneous doses. It is not one injection per week. Use only the prescribed product and supplied instructions, and have the clinician check that you can prepare, measure, store and give it correctly. Ask about site rotation, missed doses, a damaged vial and safe sharps disposal. If instructions or packaging differ from your training, contact the pharmacist before using it.
Ask the pharmacist about unused medicine disposal for the exact WR or SV product. Do not share it or keep it beyond its instructed discard date. For WR, the current instructions say to discard the mixed vial seven days after mixing and remaining bacteriostatic water 28 days after first use. Those dates must not be transferred to SV. Put used needles and syringes directly in an appropriate sharps container, not loose in household trash or recycling. Follow local sharps-disposal rules for the full container. Ask the pharmacist if you are unsure whether medicine is still usable or how to return an unused supply.
Choose the right appointment type to continue.
